BAY R3401 is an orally active glycogen phosphorylase inhibitor that can achieve irreversible and non-selective inhibition of hepatic glycogenolysis. BAY R3401 inhibits glycogenolysis in liver cells, with IC50 values of 27.06 and 52.83 µM in HL-7702 and HepG2 cells, respectively. BAY R3401 can be used for the research of type 2 diabetes[1].
Molecular Weight:
375.85
CAS Number:
[100276-03-7]
Formula:
C20H22ClNO4
Target:
Phosphorylase
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
